References
- Tüysüz B, Bursalı A, Alp Z, et al. Osteoporosis-pseudoglioma syndrome: three novel mutations in the LRP5 gene and response to bisphosphonate treatment. Horm Res Paediatr. 2012;77:115–120.
- Gong Y, Slee RB, Fukai N, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001;107:513–523.
- Yadav VK, Ryu JH, Suda N, et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell. 2008;135:825–837.
- Streeten EA, Ramirez S, Eliades M, et al. Fractures on bisphosphonates in osteoporosis pseudoglioma syndrome (OPPG): pQCT shows poor bone density and structure. Bone. 2015;77:17–23.
- McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354:821–831.
- Uehara M, Nakamura Y, Takahashi J, et al. Efficacy of denosumab for osteoporosis in three female patients with osteogenesis imperfecta. Tohoku J Exp Med. 2017;242:115–120.
- Levasseur R, Lacombe D, De Vernejoul MC. LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders. Joint Bone Spine. 2005;72:207–214.
- Somer H, Palotie A, Somer M, et al. Osteoporosis-pseudoglioma syndrome: clinical, morphological, and biochemical studies. J Med Genet. 1988;25:543–549.
- Alonso N, Soares DC, McCloskey EV, et al. Atypical femoral fracture in osteoporosis pseudoglioma syndrome associated with two novel compound heterozygous mutations in LRP5. J Bone Miner Res. 2015;30:615–620.
- Isobe F, Nakamura Y, Suzuki T, et al. Effects of denosumab on osteoporosis in three cases with anorexia nervosa and a review of the literature. Mod Rheumatol Case Rep. 2018;2:104–106.
- Uday S, Gaston CL, Rogers L, et al. Osteonecrosis of the jaw and rebound hypercalcemia in young people treated with denosumab for giant cell tumor of bone. J Clin Endocrinol Metab. 2018;103:596–603.
- Boyce RW, Varela A, Chouinard L, et al. Infant cynomolgus monkeys exposed to denosumab in utero exhibit an osteoclast-poor osteopetrotic-like skeletal phenotype at birth and in the early postnatal period. Bone. 2014;64:314–325.
- Koay MA, Tobias JH, Leary SD, et al. The effect of LRP5 polymorphisms on bone mineral density is apparent in childhood. Calcif Tissue Int. 2007;81:1–9.
- Ferrari SL, Deutsch S, Choudhury U, et al. Polymorphisms in the low-density lipoprotein receptor-related protein 5 (LRP5) gene are associated with variation in vertebral bone mass, vertebral bone size, and stature in whites. Am J Hum Genet. 2004;74:866–875.